US regulatory status: approved. Molecular target: Betaine-homocysteine S-methyltransferase.
- Target
- Betaine-homocysteine S-methyltransferase
- Mechanism
- Betaine-homocysteine S-methyltransferase substrate
pharma
Recordati Rare Diseases
Recordati Rare Diseases Australia Pty.
Recordati Rare Diseases drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Puteaux, AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- Puteaux, AU
- Programs
- 0
- Drugs
- 4
- Patents
- 0
Recordati Rare Diseases pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Recordati Rare Diseases drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
osilodrostat
Systemic hormonal preparations (H02)Systemic hormonal preparations (H02) compound in Recordati Rare Diseases's portfolio. Mechanism: Cytochrome P450 11B1 inhibitor.
- Mechanism
- Cytochrome P450 11B1 inhibitor
-
Development asset linked to Recordati Rare Diseases in public FDA and regional records. Molecular target: Somatostatin receptor type 1.
- Target
- Somatostatin receptor type 1
- Mechanism
- Somatostatin receptor 1 agonist
-
siltuximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6.
- Target
- Interleukin-6
- Mechanism
- Interleukin-6 inhibitor